Asia300

Dr. Reddy's Laboratories Ltd.

India

  • 1m
  • 3m
  • 6m
  • 1y
  • 2y
  • 5y
May 24, 2017
Prev close: 2,520.55
May 24, 2017
Market cap:
Market cap(USD):
417,593.96M
6,447.18M
Shares: 165.67M

Currency in INR

Company profile

Market(Ticker): BOM(500124)
Sector:
Industry:
Health Technology
Pharmaceuticals: Generic
Full time employees: --

Business summary

Dr. Reddy's Laboratories Ltd. engages in the manufacture and market of pharmaceutical products. It operates through the following segments: Pharmaceutical Services and Active Ingredient; Global Generics; and Proprietary Products. The Pharmaceutical Services and Active Ingredients segments includes active pharmaceutical ingredients and intermediaries also known as active pharmaceutical products or bulk drug; it also provides research services. The Global Generics segment consists of finished pharmaceutical products ready for consumption. The Proprietary Products segment involves the discovery of new chemical entities for subsequent commercialization and out-licensing. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Company background

Dr. Reddy's Laboratories is a leading Indian generic drugmaker that operates business in more than 20 countries. Founder K. Anji Reddy is among the business leaders who spearheaded the development of India's generic drug industry.

The company was founded in 1984, and its generic drug business found its way to a growth track in 1986. It continues to steadily expand in 2000s. It has made acquisitions and now has development bases in the U.K. and the Netherlands.

Dr. Reddy's Laboratories has been stepping up its biomedicine operations. These include the development of anti-cancer drugs, which the company considers a big source of future earnings. Dr. Reddy's Laboratories aims to reinforce its biomedicine operations through a tie-up with the German drugmaker Merck.

Anji Reddy died in 2013. His son, Satish Reddy, serves as company chairman and his son-in-law as co-chairman. The founding family owns nearly 25% of the company's shares.

In the news

Financial highlights

Mar 2017

  • Local currency
  • US Dollar
Revenue 141,961M
Gross profit 85,729M
Operating income 14,830M
Income before tax 15,537M
Net income 12,921M
EBITDA 25,096M
Diluted EPS 77.37
Dividends per share --
Total assets 218,165M
Total liabilities 95,544M
Total equity 122,621M
Operating cash flow --

Currency in INR

Revenue 2,117.01M
Gross profit 1,278.44M
Operating income 221.15M
Income before tax 231.69M
Net income 192.68M
EBITDA 374.24M
Diluted EPS 1.15
Dividends per share --
Total assets 3,359.74M
Total liabilities 1,471.37M
Total equity 1,888.36M
Operating cash flow --

Currency in USD

Valuation measures

Mar 2017

PER 33.95
ROA 6.06%
ROE 10.29%
Operating margin 10.44%
Profit margin 9.10%

Key executive

  • Co-Chairman, Chief Executive Officer & MD: Gunupati Venkateswara Prasad
  • President, CFO & Global Head-IT: Saumen Chakraborty
  • Chief Operating Officer: Abhijit Mukherjee
  • Secretary & Compliance Officer: Sandeep Poddar
  • EVP, Head-Emerging Markets & Global Generics: M. V. Ramana

Share holders

  • Dr. Reddy's Holdings Ltd.(24.5%)
  • First State Investment Management (UK) Ltd.(7.0%)
  • OppenheimerFunds, Inc.(5.2%)
  • BlackRock Fund Advisors(2.0%)
  • Abu Dhabi Investment Authority (Investment Management)(1.9%)
  • Franklin Templeton Asset Management (India) Pvt Ltd.(1.5%)
  • Life Insurance Corp. of India(1.4%)
  • GIC Pte Ltd. (Investment Management)(1.4%)
  • TELUK KEMANG INVESTMENTS MAURITIUS LTD(1.4%)
  • Vontobel Asset Management, Inc.(1.1%)

Address

  • Website: http://www.drreddys.com
  • Address: Door No. 8-2-337, Road No. 3, Hyderabad, 500034, India
  • Phone: +91.40.49002900

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.